Hostname: page-component-745bb68f8f-b95js Total loading time: 0 Render date: 2025-01-11T06:58:29.625Z Has data issue: false hasContentIssue false
  • English
  • Français

Buprenorphine Supply, Access, and Quality: Where We Have Come and the Path Forward

Published online by Cambridge University Press:  01 January 2021

Christopher T. Breen  and
David A. Fiellin
Get access Rights & Permissions [Opens in a new window]

Extract

Buprenorphine is a form of opioid agonist treatment that has been demonstrated to be an effective medication for opioid addiction. It is available in different formulations and marketed under various trade names, including commonly as a buprenorphine/naloxone combination. This paper provides an overview of existing literature on the supply of buprenorphine treatment, the ability of people to access treatment with buprenorphine, and the quality of treatment received. We argue that better data for each of these aspects of treatment could inform policy to expand effective treatment with buprenorphine, and we suggest steps to obtain and act on such data.

Type
Symposium Articles
Information
Journal of Law, Medicine & Ethics , Volume 46 , Issue 2: Law and the Opioid Crisis: An Inter-Disciplinary Examination , Summer 2018 , pp. 272 - 278
Copyright
Copyright © American Society of Law, Medicine and Ethics 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Drug Overdose Death Data, available at <https://www.cdc.gov/drugoverdose/data/statedeaths.html> (last visited Jan. 24, 2018).+(last+visited+Jan.+24,+2018).>Google Scholar
Hedegaard, H., Warner, M., and Miniño, A. M., Drug Overdose Deaths in the United States, 1999–2016, NCHS Data Brief, no 294 (Hyattsville, MD: National Center for Health Statistics, 2017).Google Scholar
Mattick, R. P., Breen, C., Kimber, J., and Davoli, M., “Buprenorphine Maintenance Versus Placebo or Methadone Maintenance for Opioid Dependence,” Cochrane Database of Systematic Reviews, no. 2 (2014): CD002207.Google Scholar
Volkow, N.D., Frieden, T.R., Hyde, P.S., and Cha, S.S., Perspective, “Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic,” New England Journal of Medicine 370, no. 22 (2014): 2063-2066.CrossRefGoogle Scholar
21 U.S.C. § 823 (2018).Google Scholar
Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services, Methadone, available at <https://www.samhsa.gov/medication-assisted-treatment/treatment/methadone> (last visited Feb. 21, 2018).+(last+visited+Feb.+21,+2018).>Google Scholar
See supra note 5.Google Scholar
42 C.F.R. § 8.610 (2018).Google Scholar
21 U.S.C. § 823 (2018).Google Scholar
Jones, C. M., Campopiano, M., Baldwin, G., and McCance-Katz, E., “National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment,” American Journal of Public Health 105, no. 8 (2015): 55-63.CrossRefGoogle Scholar
Rosenblatt, R. A., Andrilla, C. H., Catlin, M., and Larson, E. H., “Geographic and Specialty Distribution of US Physicians Trained to Treat Opioid Use Disorder,” Annals of Family Medicine 13, no. 1 (2015): 23-26.CrossRefGoogle Scholar
Id.; Sigmon, S. C., “Access to Treatment for Opioid Dependence in Rural America: Challenges and Future Directions,” JAMA Psychiatry 71, no. 4 (2014): 359-360.CrossRefGoogle Scholar
Huhn, A. S. and Dunn, K. E., “Why Aren’t Physicians Prescribing More Buprenorphine?” Journal of Substance Abuse Treatment 78 (2017): 1-7.CrossRefGoogle Scholar
Id.Google Scholar
Turner, L., Kruszewski, S. P., and Alexander, G. C., “Trends in the Use of Buprenorphine by Office-Based Physicians in the United States, 2003-2013,” American Journal on Addictions 24, no. 1 (2015): 24-29.CrossRefGoogle Scholar
Dick, A. W., Pacula, R. L., Gordon, A. J., Sorbero, M., Burns, R. M., Leslie, D., and Stein, B. D., “Growth in Buprenorphine Waivers for Physicians Increased Potential Access to Opioid Agonist Treatment, 2002-11,” Health Affairs 34, no. 6 (2015): 1028-1034.CrossRefGoogle Scholar
Knudsen, H. K., Havens, J. R., Lofwall, M. R., Studts, J. L., and Walsh, S. L., “Buprenorphine Physician Supply: Relationship with State-Level Prescription Opioid Mortality,” Drug and Alcohol Dependence 173, Supplement 1 (2017): S55-S64.CrossRefGoogle Scholar
Stein, B. D., Pacula, R. L., Gordon, A. J., Burns, R. M., Leslie, D. L., Sorbero, M. J., Bauhoff, S., Mandell, T. W., and Dick, A. W., “Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties,” Milbank Quarterly 93, no. 3 (2015): 561-583.CrossRefGoogle Scholar
Id.Google Scholar
Id.Google Scholar
Stein, B. D., Sorbero, M., Dick, A. W., Pacula, R. L., Burns, R. M., and Gordon, A. J., “Physician Capacity to Treat Opioid Use Disorder with Buprenorphine-Assisted Treatment,” JAMA 316, no. 11 (2016): 1211-1212; C. P. Thomas, E. Doyle, P. W. Kreiner, C. M. Jones, J. Dubenitz, A. Horan, and B. D. Stein, “Prescribing Patterns of Buprenorphine Waivered Physicians,” Drug and Alcohol Dependence 181 (2017): 213-218.CrossRefGoogle Scholar
Polydorou, S., Gunderson, E. W., and Levin, F. R., “Training Physicians to Treat Substance Use Disorders,” Current Psychiatry Reports 10, no. 5 (2008): 399-404.CrossRefGoogle Scholar
Gunderson, E. W., Fiellin, D. A., Levin, F. R., Sullivan, L. E., and Kleber, H. D., “Evaluation of a Combined Online and in Person Training in the Use of Buprenorphine,” Substance Abuse 27, no. 3 (2006): 39-45; See also D. T. Barry, K. S. Irwin, E. S. Jones, W. C. Becker, J. M. Tetrault, L. E. Sullivan, H. Hansen, et al., “Integrating Buprenorphine Treatment into Office-Based Practice: A Qualitative Study,” Journal of General Internal Medicine 24, no. 2 (2009): 218-225.CrossRefGoogle Scholar
Levin, F. R., Bisaga, A., Sullivan, M. A., Williams, A. R., and Cates-Wessel, K., “A Review of a National Training Initiative to Increase Provider Use of MAT to Address the Opioid Epidemic,” American Journal on Addictions 25, no. 8 (2016): 603-609; J. E. Egan, P. Casadonte, T. Gartenmann, J. Martin, E. F. McCance-Katz, J. Netherland, J. A. Renner, L. Weiss, A.J. Saxon, and D. A. Fiellin, “The Physician Clinical Support System-Buprenorphine (PCSS-B): A Novel Project to Expand/Improve Buprenorphine Treatment,” Journal of General Internal Medicine 25, no. 9 (2010): 936-941.CrossRefGoogle Scholar
Parran, T. V., Muller, J. Z., Chernyak, E., Adelman, C., Delos Reyes, C. M., Rowland, D., and Kolganov, M., “Access to and Payment for Office-Based Buprenorphine Treatment in Ohio,” Substance Abuse: Research and Treatment 11 (2017): 1-6.Google Scholar
Hansen, H. B., Siegel, C. E., Case, B. G., Bertollo, D. N., DiRocco, D., and Galanter, M., “Variation in Use of Buprenorphine and Methadone Treatment by Racial, Ethnic and Income Characteristics of Residential Social Areas in New York City,” Journal of Behavioral Health Services & Research 40, no. 3 (2013): 367-377.CrossRefGoogle Scholar
Wen, H., Hockenberry, J. M., Borders, T. F., and Druss, B. G., “Impact of Medicaid Expansion on Medicaid-Covered Utilization of Buprenorphine for Opioid Use Disorder Treatment,” Medical Care 55, no. 4 (2017): 336-341; J.C. Maclean and B. Saloner, “The Effect of Public Insurance Expansions on Substance Use Disorder Treatment: Evidence from the Affordable Care Act,” NBER Working Paper 23342 (Cambridge, MA: National Bureau of Economic Research, 2017).CrossRefGoogle Scholar
Knudsen, H. K., “The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis,” Journal of Studies on Alcohol and Drugs 76, no. 4 (2015): 644-654.CrossRefGoogle Scholar
Kermack, A., Flannery, M., Tofighi, B., McNeely, J., and Lee, J. D., “Buprenorphine Prescribing Practice Trends and Attitudes among New York Providers,” Journal of Substance Abuse Treatment 74 (2017): 1-6.CrossRefGoogle Scholar
American Society of Addiction Medicine, Advancing Access to Addiction Medications: Implications for Opioid Addiction Treatment (2013).Google Scholar
Burns, R. M., Pacula, R. L., Bauhoff, S., Gordon, A. J., Hendrikson, H., Leslie, D. L., and Stein, B. D., “Policies Related to Opioid Agonist Therapy for Opioid Use Disorders: The Evolution of State Policies from 2004 to 2013,” Substance Abuse 37, no. 1 (2016): 63-69.CrossRefGoogle Scholar
Kaiser Family Foundation, States Reporting Managed Care Pharmacy Uniform Preferred Drug List Requirements, available at <https://www.kff.org/medicaid/state-indicator/states-reporting-managed-care-pharmacy-uniform-preferred-drug-list-pdl-requirements> (last visited Jan. 24, 2018).+(last+visited+Jan.+24,+2018).>Google Scholar
See American Society of Addiction Medicine, supra note 30.Google Scholar
Clark, R. E., Baxter, J. D., Barton, B. A., Aweh, G., O’Connell, E., and Fisher, W. H., “The Impact of Prior Authorization on Buprenorphine Dose, Relapse Rates, and Cost for Massachusetts Medicaid Beneficiaries with Opioid Dependence,” Health Services Research 49, no. 6 (2014): 1964-1979.Google Scholar
Harper, J., “Indiana Just Made Getting Addiction Treatment A Little Bit Easier,” WYFI Indianapolis, November 17, 2017, available at <https://www.wfyi.org/news/articles/indiana-just-made-getting-addiction-treatment-a-little-bit-easier> (last visited Jan. 24, 2018).+(last+visited+Jan.+24,+2018).>Google Scholar
Luthra, S., “Another Big Health Insurer Loosens Rules for Addiction Treatment,” NPR News, February 15, 2017, available at <https://www.npr.org/sections/health-shots/2017/02/15/515239382/another-big-health-insurer-loosens-rules-for-covering-addiction-treatment> (last visited Jan. 24, 2018).+(last+visited+Jan.+24,+2018).>Google Scholar
Wakeman, S. E., “Why It’s Inappropriate Not to Treat Incarcerated Patients with Opioid Agonist Therapy,” AMA Journal of Ethics 19, no. 9 (2017): 922-930.Google Scholar
Id.Google Scholar
Bruce, R. D. and Schleifer, R. A., “Ethical and Human Rights Imperatives to Ensure Medication-Assisted Treatment for Opioid Dependence in Prisons and Pre-Trial Detention,” International Journal of Drug Policy 19, no. 1 (2008): 17-23.CrossRefGoogle Scholar
Krawczyk, N., Picher, C. E., Feder, K. A., and Saloner, B., “Only One in Twenty Justice-Referred Adults in Specialty Treatment for Opioid Use Receive Methadone or Buprenorphine,” Health Affairs (Millwood), 36, no. 12 (2017): 2046-2053.CrossRefGoogle Scholar
Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services, Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction, Treatment Improvement Protocol (TIP) Series, No. 40 (Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004); K. Kampman and M. Jarvis, “American Society of Addiction Medicine (ASM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use,” Journal of Addiction Medicine 9, no. 5 (2015): 358-367.Google Scholar
“Goals & Objectives,” PCSS MAT Training, available at <https://pcssmat.org/about/goals-objectives/#develop> (last visited February 6, 2018).+(last+visited+February+6,+2018).>Google Scholar
Fiellin, D. A., O’Connor, P. G., Chawarski, M., and Schottenfeld, R. S., “Processes of Care During a Randomized Trial of Office-Based Treatment of Opioid Dependence in Primary Care,” American Journal on Addictions 13, Supplement 1 (2004): S67-S78.CrossRefGoogle Scholar
Gellad, W. F., Zhao, X., Thorpe, C. T., et al., “Overlapping Buprenorphine, Opioid, and Benzodiazepine Prescriptions Among Veterans Dually Enrolled in VA and Medicare Part D,” Substance Abuse 38, no. 1 (2017): 22-25; B. Mund and K. Stith, “Buprenorphine MAT as an Imperfect Fix,” Journal of Law, Medicine & Ethics 46, no. 2 (2018): 279-291.CrossRefGoogle Scholar
Gordon, A. J., Lo-Ciganic, W. H., Cochran, G., Gellad, W. F., Cathers, T., Kelley, D., and Donohue, J. M., “Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program,” Journal of Addiction Medicine 9, no. 6 (2015): 470-477Google Scholar
Gordon, A., Lo-Ciganic, W. H., Cochran, G., Gellad, W. F., Cathers, T., and Donohue, J. M., “Treatment Quality for Buprenorphine Care: The Pot at the End of the Rainbow,” Journal of Addiction Medicine 10, no. 3 (2016): 210-211.CrossRefGoogle Scholar
Sherrick, R. C., “Measuring Quality of Buprenorphine Care,” Journal of Addiction Medicine 10, no. 3 (2016): 209-210.CrossRefGoogle Scholar
Butler, J., Becker, W., and Humphries, K., “Big Data and the Opioid Crisis: Balancing Patient Privacy with Public Health,” Journal of Law, Medicine & Ethics 46, no. 2 (2018): 440-453.CrossRefGoogle Scholar
Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services, “HHS Makes Effort to Increase Access to Treatment of Opioid Use Disorder,” Buprenorphine Prescriber News (Winter 2017), available at <http://www.dsgonline.com/DataWaiver/enews/2017/2017_11_28/dw_enews_web.html> (last visited January 24, 2018).+(last+visited+January+24,+2018).>Google Scholar
Vestal, C., “Nurse Licensing Laws Block Treatment for Opioid Addiction,” The Pew Charitable Trusts, Stateline, April 21, 2017, available at <http://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2017/04/21/nurse-licensing-laws-block-treatment-for-opioid-addiction> (last visited February 3, 2018).+(last+visited+February+3,+2018).>Google Scholar
Legal Action Center, Legality of Denying Access to Medication Assisted Treatment in the Criminal Justice System, December 1, 2011; National Association of Drug Court Professionals, Adult Drug Court Best Practice Standards Volume I, (2013); Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services, Einstein Expert Panel: Medication-Assisted Treatment and the Criminal Justice System, Report of Proceedings, September 10, 2013.Google Scholar
Eibl, J. K., Gauthier, G., Pellegrini, D., Daiter, J., Varenbut, M., Hogenbirk, J. C., and Marsh, D. C., “The Effectiveness of Tele-medicine-Delivered Opioid Agonist Therapy in a Supervised Clinical Setting,” Drug and Alcohol Dependence 176 (2017): 133-138.CrossRefGoogle Scholar
Suzuki, J., Zinser, J., Klaiber, B., Hannon, M., Grassi, H., Spinosa, M., Ramirez, A., Issa, M., and Chin Feman, S. P., “Feasibility of Implementing Shared Medical Appointments (SMAs) for Office-Based Opioid Treatment with Buprenorphine: A Pilot Study,” Substance Abuse 36, no. 2 (2015): 166-169.CrossRefGoogle Scholar
Fox, A. D., Chamberlain, A., Sohler, N. L., Frost, T., and Cunningham, C. O., “Illicit Buprenorphine Use, Interest in and Access to Buprenorphine Treatment among Syringe Exchange Participants,” Journal of Substance Abuse Treat 48, no. 1 (2015): 112-116; M. R. Lofwall, and S. L. Walsh, “A Review of Buprenorphine Diversion and Misuse: The Current Evidence Base and Experiences from around the World,” Journal of Addiction Medicine 8, no. 5 (2014): 315-326.CrossRefGoogle Scholar
Olsen, Y. and Sharfstein, J. M., “Confronting the Stigma of Opioid Use Disorder — and Its Treatment,” JAMA 311, no. 14 (2014): 1393-1394.CrossRefGoogle Scholar